Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Assets: 2021-2025

Historic Assets for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Krystal Biotech's Assets rose 26.24% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 26.24%. This contributed to the annual value of $1.1 billion for FY2024, which is 29.02% up from last year.
  • Per Krystal Biotech's latest filing, its Assets stood at $1.2 billion for Q3 2025, which was up 8.93% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Assets peaked at $1.2 billion during Q3 2025, and registered a low of $443.0 million during Q1 2021.
  • Moreover, its 3-year median value for Assets was $917.7 million (2024), whereas its average is $917.0 million.
  • As far as peak fluctuations go, Krystal Biotech's Assets declined by 13.78% in 2023, and later surged by 60.44% in 2024.
  • Quarterly analysis of 5 years shows Krystal Biotech's Assets stood at $626.3 million in 2021, then declined by 10.83% to $558.5 million in 2022, then surged by 46.54% to $818.4 million in 2023, then grew by 29.02% to $1.1 billion in 2024, then increased by 26.24% to $1.2 billion in 2025.
  • Its Assets stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.